EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitSystematische Übersicht

Glucagon Like Peptide-1 Receptor Agonists for Sarcopenia and Muscle Wasting Disorders: A Systematic Review of Efficacy and Mechanisms

Abudureheman Maihemuti, Can Cui, Qianjin Wang, Reziwanguli Amuti, Wai Wang Chau, Senlin Chai, Ning Zhang, Ronald Man Yeung Wong, Ho Ko, Timothy Chi-Yui Kwok, Wing-Hoi Cheung

aging and disease · 2025

DOI: 10.14336/ad.2025.1165 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift aging and disease, 2025. Verfasst von Abudureheman Maihemuti und 10 weiteren Autor:innen. Beteiligte Einrichtung: Musculoskeletal Research Laboratory, Department of Orthopaedics and Traumatology, The Chinese University of Hong Kong, Hong Kong, China. Die Arbeit wurde bisher 6-mal zitiert (Crossref).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Muscle wasting disorders, including sarcopenia and skeletal muscle atrophy, are increasingly prevalent among older adults and those with metabolic comorbidities. Sarcopenia, a progressive age-associated condition, involves the decline in skeletal muscle mass, strength, and physical performance, affecting millions of people globally. These disorders significantly elevate the risks of frailty, falls, and premature mortality, contributing to a growing burden on healthcare systems. Current interventions, including resistance exercise and dietary supplementation, have shown limited effectiveness, particularly among individuals with concurrent conditions such as type 2 diabetes (T2D). Notably, glucagon-like peptide-1 receptor agonists (GLP-1RAs), initially developed for glycemic and weight control, have demonstrated promising effects in preclinical models of muscle degeneration. In this review, we analyzed 20 preclinical and clinical studies on sarcopenia and muscle wasting disorders. Animal studies yielded promising results, including increased grip strength and enhanced skeletal muscle cross-sectional area (CSA), while body weight remained stable within a defined dosage range. Mechanistically, GLP-1RAs mitigate muscle wasting by upregulating myogenic factors (MyoD, MyoG), promoting mitochondrial biogenesis, and suppressing proteolysis (MuRF1, MAFbx) and inflammation via AMPK/SIRT1/NF-κB/Myostatin signaling. In contrast, limited clinical studies showed body weight reduction accompanied by a decline in lean mass following GLP-1RA treatment. Collectively, these results highlight the low dose-dependent anabolic potential of GLP-1RAs on skeletal muscle, while clinical evidence indicates simultaneous weight and lean mass loss. These findings suggest low-dose GLP-1RAs as potential therapy for sarcopenic obesity or early sarcopenia with metabolic comorbidities, warranting comprehensive clinical trials that incorporate multimodal strategies to preserve muscle mass during treatment.

Autor:innen und Institutionen

  • Musculoskeletal Research Laboratory, Department of Orthopaedics and Traumatology, The Chinese University of Hong Kong, Hong Kong, China.
  • Li Ka Shing Institute of Health Sciences, The Chinese University of Hong Kong, Hong Kong SAR China.
  • Department of Respiratory Medicine, Shenzhen Heng Sheng Hospital, Shenzhen, China.
  • Division of Neurology, Department of Medicine and Therapeutics, and Gerald Choa Neuroscience Institute, The Chinese University of Hong Kong, Hong Kong, China.
  • Department of Medicine and Therapeutics, Faculty of Medicine, Chinese University of Hong Kong, Hong Kong, China.

Zitieren

APA

Maihemuti, A., Cui, C., Wang, Q., Amuti, R., Chau, W. W., Chai, S., Zhang, N., Wong, R. M. Y., Ko, H., Kwok, T. C., & Cheung, W. H. (2025). Glucagon Like Peptide-1 Receptor Agonists for Sarcopenia and Muscle Wasting Disorders: A Systematic Review of Efficacy and Mechanisms. aging and disease. https://doi.org/10.14336/ad.2025.1165

Vancouver

Maihemuti A, Cui C, Wang Q, Amuti R, Chau WW, Chai S, et al. Glucagon Like Peptide-1 Receptor Agonists for Sarcopenia and Muscle Wasting Disorders: A Systematic Review of Efficacy and Mechanisms. aging and disease. 2025. doi:10.14336/ad.2025.1165

BibTeX
@article{Maihemuti2025,
  author = {Maihemuti, Abudureheman and Cui, Can and Wang, Qianjin and Amuti, Reziwanguli and Chau, Wai Wang and Chai, Senlin and Zhang, Ning and Wong, Ronald Man Yeung and Ko, Ho and Kwok, Timothy Chi-Yui and Cheung, Wing-Hoi},
  title = {Glucagon Like Peptide-1 Receptor Agonists for Sarcopenia and Muscle Wasting Disorders: A Systematic Review of Efficacy and Mechanisms},
  journal = {aging and disease},
  year = {2025},
  doi = {10.14336/ad.2025.1165}
}
Kostenlos starten →